Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease

28 septembre 2026 mis à jour par: XellSmart Therapeutics (Shanghai) Co., Ltd.

A Phase I/II Clinical Study on the Safety, Tolerability, and Efficacy of Stereotactic Intracerebral Transplantation of Human Allogeneic iPSC-derived Dopaminergic Neuronal Precursor Cells (XS411 Cell Injection) for the Treatment of Parkinson's Disease

This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease.

This Phase II clinical trial is designed to evaluate the safety, tolerability and Efficacy of XS411 (derived dopaminergic neural progenitor cell injection) in patients with Parkinson's disease.

Aperçu de l'étude

Description détaillée

This is a phase I clinical study to evaluate the safety and tolerability of human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection (XS411CN) via brain stereotactic transplantation for the treatment of primary Parkinson's disease.

The study adopts a single-arm, open-label, non-randomized dose-escalation design to evaluate the safety, tolerability, and preliminary efficacy of stereotactic brain transplantation of XS411CN in patients with primary Parkinson's disease and explore the optimal recommended dose. 12 to 18 patients with primary Parkinson's disease are planned to be enrolled.

On the day of cell transplantation surgery, the planned dose of XS411CN is transplanted into the bilateral putamen of the subjects by brain stereotactic technology.

After receiving the XS411CN transplantation, the subjects will receive immunosuppressants. All subjects receive standard treatment at the same time.

Each patient receives a safety observation period of 28 days after cell transplantation with XS411CN. This study adopts the traditional "3+3 " dose escalation method. The trial starts with a low dose and the dose will be increased gradually. Each subject will be closely observed for 7 days after surgery, and the dose-limiting toxicity (DLT) events that may occur within 28 days after the first transplant treatment will be evaluated.

Type d'étude

Interventionnel

Inscription (Réel)

39

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100070
        • Beijing Tiantan Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

50 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Male or female, aged between 50 and 75 years old;
  2. Diagnosed as 'clinically established PD' consistent with MDS clinical Diagnostic Criteria for Parkinson's disease,
  3. A minimum of 5 years since diagnosis;
  4. Hoehn- Yahr score during the off-time is 3 to 4;
  5. The subjects with an average of at least 2.5 hours of "off time" per day;
  6. Stable anti-PD therapy for at least 1 month before screening;
  7. Anti-PD treatment was once effective, but the efficacy has declined significantly or drug-induced motor complications have occurred, affecting the quality of life;
  8. Positive levodopa challenge test (MDS-UPDRS-III score improvement from off- state to on- state > 30%);
  9. At least three months before the first administration, the subject should have completed all vaccinations as recommended by local authorities;
  10. The results of complete blood count meet the following conditions: ANC ≥ 2.0×109 /L, WBC ≥ 4.0×109 /L, PLT≥ 100×109 /L, HGB ≥ 10g/dL
  11. The patient or his/her legal guardian agree to accept the study and signed the informed consent form in writing.

Exclusion Criteria:

  1. Parkinsonian syndrome or secondary Parkinson's disease (Atypical Parkinson's syndrome (Parkinson's plus syndrome, secondary Parkinson's syndrome, hereditary degenerative Parkinson's syndrome);

  2. Patients are in advanced stages of Parkinson's disease and are experiencing severe, disabling peak-dose dyskinesia or biphasic dyskinesia and/or unpredictable or widely fluctuating symptoms;

  3. Severe cognitive impairment (MMSE<24, poor compliance due to dementia, inability to accurately record diaries, and/or inability to sign informed consent;

  4. Those with a history of severe mental illness, or those with severe suicidal tendencies as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS), or those with suicidal ideation in the past 12 months, or those who have attempted suicide in the past 5 years;

  5. Patients with severe brain atrophy, space-occupying lesions, hydrocephalus, cerebral vascular malformations as indicated by head CT/MRI, and those with structural abnormalities that may affect transplantation or increase surgical risks as determined by the investigators;

  6. Currently with active internal bleeding; or arterial puncture at a site that is difficult to stop bleeding within 1 week before screening; or gastrointestinal or urinary bleeding within 3 weeks before screening;

  7. History of striatal or extrapyramidal surgery, including but not limited to deep brain stimulation (DBS) surgery and globus pallidus lesion;

  8. Coagulation abnormalities;

  9. Abnormal liver and kidney function laboratory tests during the screening period;

  10. The patient is currently receiving or has previously received the following treatments:

    • Use of benzodiazepines at a dose level equal to or higher than the recommended dose in Package Insert for more than 4 weeks cumulatively since one month before enrollment, immunosuppressants (except for the immunosuppressants to be used in this study), or antipsychotics within 3 months before treatment;
    • Use of botulinum toxin, phenol, subarachnoid baclofen injection, or interventional treatment for dystonia or spasticity within 6 months before treatment;
    • Have a history of epilepsy or use anti-epileptic drugs for prevention;
    • Received cell therapy within 3 months before screening;
  11. Contraindications to general anesthesia or stereotactic surgery (such as sleep apnea, chronic obstructive pulmonary disease, etc.), MRI or PET examinations;

  12. Those with the following abnormalities in the past or detected (if any of the following is met, they will be excluded):

    • Evidence of congestive heart failure or history of end-stage cardiovascular disease;
    • Severe arrhythmias and poorly controlled arrhythmias;
    • Clinically significant electrocardiogram abnormalities during the screening or baseline period;
    • History of unstable angina or acute myocardial infarction within the past 3 months;
    • Diabetic patients with poor glycemic control;
    • Hypertensive patients with poorly controlled blood pressure;
  13. Patients with active infection during the screening period (except mild local skin infection) that need antibiotic, antifungal, or antiviral treatment but infection is still not under control;

  14. The presence of severe lung diseases during the screening period;

  15. Patients with uncontrolled autoimmune diseases;

  16. During the screening period, patients have severe arthritis, limp, severe sequelae of stroke, severe osteoporosis, or history of severe trauma within 1 month, etc., which the investigators assess may affect the evaluations;

  17. Any history of malignancy, excluding cured basal cell carcinoma and/or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or ductal carcinoma of the breast;

  18. Serious infectious diseases;

  19. Pregnant or lactating women, women who plan to become pregnant during the study and within 6 months after the end of the study, or women who are unwilling to use effective contraceptive measures;

  20. Patients who have participated in other clinical studies of drugs or medical devices within 3 months before treatment;

  21. Have a long history of alcoholism or drug abuse;

  22. Patients with a history of severe allergies or allergies to investigational drugs and immunosuppressants;

  23. Any other conditions that the investigator considers unsuitable for participation in the study.

  24. Severe depression

  25. Hallucinations, and hallucinations still exist after optimizing Parkinson's medications

  26. Patients have undergone MRI-guided focused ultrasound thalamotomy

  27. Used immunosuppressants within 3 months, except for the immunosuppressants to be used in this study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Traitement standard
Expérimental: 4,5 × 10 ^ 6 cellules / putamen bilatéral

5.0×10^7 cells/mL, injection, single dose

Expérimental: 9,0 × 10 ^ 6 cellules / putamen bilatéral

5.0×10^7 cells/mL, injection, single dose

Expérimental: 1,8 × 10 ^ 7 cellules / putamen bilatéral

5.0×10^7 cells/mL, injection, single dose

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To evaluate the safety and tolerability of XS411CN in treatment of primary Parkinson's disease
Délai: 28 days after administration of XS411CN

To evaluate the safety and tolerability of XS411CN in treatment of primary Parkinson's disease through:

1)The occurrence and incidence of adverse events and serious adverse events (adverse event grading criteria are based on NCI-CTCAE V5.0) 28 days after administration of XS411CN; 2) Changes in vital signs, laboratory tests, 12-lead electrocardiogram, etc. compared with baseline after administration of XS411CN;

28 days after administration of XS411CN
MDS-UPDRS Part III score during the 'OFF' state
Délai: Month 12

Change from baseline in MDS-UPDRS Part III (Motor Examination) score during the 'OFF' state at 12 months after administration of XS411 cell injection

Month 12

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
MDS-UPDRS Part III score during the 'OFF' state
Délai: Baseline, Month 3, Month 6, Month 9

Change from baseline in MDS-UPDRS Part III (Motor Examination) score during the 'OFF' state at 3 months, 6 months, 9 months after administration of XS411 cell injection

Baseline, Month 3, Month 6, Month 9

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 août 2025

Achèvement primaire (Estimé)

1 juillet 2027

Achèvement de l'étude (Estimé)

1 juillet 2028

Dates d'inscription aux études

Première soumission

9 juillet 2025

Première soumission répondant aux critères de contrôle qualité

18 juillet 2025

Première publication (Réel)

23 juillet 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 septembre 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner